Gene Therapy and Gamified Insurance Reshape Health Care

Two groundbreaking developments in American health care emerged this week, each offering a radically different approach to preventing disease: a single-infusion CRISPR gene therapy that dramatically slashes cholesterol, and a life insurance program that turns healthy habits into a game with real financial rewards.

One-and-Done Heart Disease Prevention?

Scientists reported on May 25 that an experimental CRISPR-Cas9 gene-editing drug called CTX310 reduced LDL cholesterol by up to 60% and triglycerides by approximately 55% in an expanded interim analysis of 35 patients. The findings, published in The New England Journal of Medicine, suggest that a single intravenous infusion could one day eliminate the need for daily statin therapy.

Developed by CRISPR Therapeutics, CTX310 works by delivering lipid nanoparticles carrying CRISPR-Cas9 to the liver, where it permanently edits the ANGPTL3 gene — turning off a protein that regulates lipid metabolism. People born with natural mutations that disable this gene have lifelong low cholesterol and triglyceride levels without apparent harmful effects.

“This is really unprecedented,” said Dr. Luke J. Laffin, lead study author and preventive cardiologist at Cleveland Clinic. “A single treatment that simultaneously lowered LDL cholesterol and triglycerides. If confirmed in larger trials, this one-and-done approach could transform care for people with lifelong lipid disorders and dramatically reduce cardiovascular risk.”

Dr. Steven E. Nissen, co-author and chief academic officer at the Cleveland Clinic Heart, Vascular and Thoracic Institute, highlighted a critical challenge the therapy could address: “Adherence to cholesterol-lowering therapy is one of the biggest challenges in preventing heart disease. Many patients stop taking their cholesterol medications within the first year. The possibility of a one-time treatment with lasting effects could be a major clinical advance.”

The initial Phase 1 trial of 15 patients was first presented in November 2025 at the American Heart Association Scientific Sessions. The expanded analysis now includes 35 participants across six sites in Australia, New Zealand, and the United Kingdom, with plans for up to 85 participants. Reductions in cholesterol appeared within two weeks and were sustained through at least 60 days of follow-up.

Safety data showed three participants experienced minor infusion-related reactions — back pain and nausea — that resolved with medication. One participant with pre-existing elevated liver enzymes had a temporary further rise that resolved without treatment. No serious or long-term safety concerns were observed. The FDA requires 15-year long-term safety monitoring for all CRISPR-based therapies.

When Life Insurance Becomes a Game

In a separate but complementary development, John Hancock life insurance company is rewriting the rules of its industry through its Vitality program, which rewards policyholders with points, prize wheels, and premium discounts for healthy behaviors.

As reported by NPR, members earn points for going to the gym, buying healthy foods, tracking sleep, and getting preventive screenings. These points translate into discounts on smartwatches, Amazon or Starbucks gift cards, hotel deals, and even savings on fruits and vegetables. Customers can save up to 25% on premiums depending on their program tier.

“We call this the life insurance business,” said Brooks Tingle, CEO of John Hancock. “But the reality is that for hundreds of years the focus was on death. It was all about, hey, you’re going to die, you should be prepared. What we’ve done is literally turn that around. This is about living, and living better.”

The company’s logic is straightforward: healthier customers live longer, pay premiums longer, and are more profitable. “The longer we’re able to collect and invest the premiums, the more money we make,” Tingle said. “You want to live a long, healthy life? It’s good for us, too.”

Early results are promising. In testimony to the House Ways and Means Subcommittee on Health in 2025, Tingle reported that Vitality members walk twice as many steps daily as the average American, and about half of members with high blood pressure brought their levels into a healthy range within a year.

Dr. Dariush Mozaffarian, director of the Food is Medicine Institute at Tufts University, who collaborated on the program’s dietary incentives, said the gamification approach has scientific backing. “What’s exciting about gamification is it’s not just about the dollar amount, it’s about making it fun and exciting and having prizes,” he said. “Growing evidence shows that it actually works quite well.”

However, Dr. Samir Sinha, a geriatrician and aging expert at Sinai Health System in Toronto, urged caution. “There’s not enough evidence right now to say that these sorts of programs are going to actually have the intended effect” of helping people live longer, he said. “However, if this can actually ingrain some healthy behaviors that become lifelong habits, this might actually create a longevity dividend.”

Two Paths to a Healthier Future

Both stories reflect a broader shift in American health care toward prevention rather than treatment. The gene therapy approach offers a technological fix — a one-time intervention that could free millions from daily medication. The gamified insurance model takes a behavioral approach, using financial incentives and game mechanics to nudge people toward healthier choices.

Each faces significant challenges. Gene therapies have historically cost millions per patient, raising questions about access and equity. The Vitality program, meanwhile, must prove that gamification can sustain engagement over years and deliver measurable longevity improvements.

What to watch for next: Phase 2 trials for CTX310 are expected to begin in late 2025 or early 2026, with larger and more diverse patient populations. John Hancock continues to expand its Vitality program, and independent researchers are studying whether behavioral incentives can deliver a genuine longevity dividend.

For now, both developments offer a glimpse of a future where preventing disease is not just more effective — but more engaging — than treating it after it strikes.